The PennZone

  • Home
  • Business
  • Non-profit
  • Health
  • Technology
  • Financial
  • Manufacturing
  • Travel
  • Music

Nattokinase Supplement for Cardiovascular and Circulatory Support
The PennZone/10270754

Trending...
  • Food Journal Magazine Releases Its 'Best Food In Los Angeles Dining' Editorial Section
  • High-End Exterior House Painting in Boulder, Colorado
  • CryptaBox Introduces a Hardware Crypto Cold Storage Wallet
Nattokinase Heart Health Supplement
AgeImmune's Nattokinase is one of the purest professional grade supplement on the market which is beneficial for overall heart health.

NEW YORK - PennZone -- Dr. Kanevsky, D.C. C.F.M.P. introduced a new supplement to AgeImmune's product line
earlier this May 2024.
A new addition to the family is Nattokinase supplement in a form of a vegetable capsule
each containing 2,000FU (fibrin unit) representing a unit of potency, which is equal to
100mg. Dr. Kanevsky is recommending a serving size of 2 capsules. However, if you
are in excellent heart health with no family history of blood clots, 1 capsule is enough as
a preventative measure.
Nattokinase is an enzyme derived from Japanese soybean called Natto via fermentation
process with a bacteria called Bacillus subtilis. Natto has been consumed as a
traditional food in Asia for over 2000 years and is believed to be a significant contributor

More on The PennZone
  • Radarsign Redefines Crosswalk Safety with Launch of CrossCommand™ RRFB Crosswalk
  • OpenSSL Corporation Opens 2026 Advisory Committees' Elections: Shape the Future!
  • Steve Everett Jr. Named President of L.T. Hampel Corporation
  • Acuvance Acquires ROI Healthcare Solutions, Building a Dedicated Healthcare ERP Practice
  • Max Tucci Award-Winning Media Powerhouse Launches New Podcast —Executive Produced by Emmy-Winning Daytime Icons Suzanne Bass & Fran Brescia Coniglio

to the longevity of the Japanese people. Although natto has been consumed in Asia for
thousands of years, the fibrinolytic and antithrombolytic property of Nattokinasae was
only discovered in 1987. Recent studies demonstrated that high natto intake is
associated with decreased risk of cardiovascular disease.
This was a sufficient reason for Dr. Kanevsky to add Nattokinase to his line of products.
There is some early evidence that nattokinase may thin the blood and help break up
blood clots. This might protect against heart disease and conditions caused by blood
clots such as stroke, heart attack, and others.
Other studies show that nattokinase may help lower blood pressure and reduce
inflammation in the body.
Unlike traditional blood thinning medications, nattokinase is a natural, widely available
and inexpensive supplement with minimal to no side effects which makes is very

More on The PennZone
  • MILBERT.ai Brings Real Time Session Defense to Google Workspace and Google Cloud
  • Appliance Outlet Caps Off a Record-Setting 2025 Nationwide, Gears Up for Even Greater Growth in 2026
  • Perry County Real Estate Agency Partners with Internet Marketing Company
  • Philadelphia HVAC Companies Were Not Created Equal
  • Home Prices Just Hit 5X Median Income — So Americans Are Buying Businesses Instead of Houses

attractive to Dr. Kanevsky's patients searching for an all-natural approach to their
health.
Having a large database of functional medicine patients Dr Kanevsky easily analyzed
the frequency of complains of a poor heart health, circulation, blood pressure and came
to a conclusion that Nattokinase will become one of the most popular products for
AgeImmune.
As always encapsulated without harmful excipients such as magnesium stearate, silicon
dioxide or titanium dioxide, AgeImmune's Nattokinase is one of the purest professional
grade supplement on the market.
Nattokinase supplement is derived from soy. Dr. Kanevsky warns that if you are allergic
to soy, you shouldn't be taking Nattokinase. It is currently available for purchase at a
discounted price of 21.99 on AgeImmune's website and on Amazon

Contact
AgeImmine
***@netembark.com


Source: Nattokinase Heart Health Supplement
Filed Under: Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • $26 Billion Global Market by 2035 for Digital Assets Opens Major Potential for Currency Tech Company with ATM Expansion and Deployment Plans Underway
  • Peernovation 365 is Now Available
  • Snap-a-Box Brings Texas' First Robot-Cooked Chinese Takeout to Katy–Fulshear
  • UK Financial Ltd Makes History as MayaCat (SMCAT) Becomes the World's First Exchange-Traded ERC-3643 Security Token
  • SNS Research Launches SNS Market Intelligence Platform for visual market intelligence for pharma
  • Narcissist Apocalypse Marks 7 Years as a Leading Narcissistic Abuse Podcast
  • High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
  • CryptaBox Introduces a Hardware Crypto Cold Storage Wallet
  • YWWSDC Launches AI-Native Digital Asset Infrastructure, Merging Technical Innovation with US-Standard Compliance
  • High-End Exterior House Painting in Boulder, Colorado
  • Simpson and Reed Co-Founders Shardé Simpson, Esq. and Ciara Reed, Esq. Launch "Hello Wilma,"
  • Report Outlines Key Questions for Individuals Exploring Anxiety Treatment Options in Toronto
  • Rande Vick Introduces Radical Value, Challenging How Brands Measure Long-Term Value
  • Lisa Mauretti Launches Peace of Mind Travel Coaching to Guide Fearful Travelers to Discover the World with Confidence
  • New Year, New Home: Begin 2026 at Heritage at South Brunswick
  • Food Journal Magazine Releases Its 'Best Food In Los Angeles Dining' Editorial Section
  • Enders Capital: 25% Gains with Just -0.80% Maximum Monthly Drawdown in Volatile Debut Year 2025
  • CES Spotlight Highlights Need for Strategic Review as Throughput Demands Evolve
  • ASR Media, Social T Marketing & PR Announce Merger
  • $780,000 Project for New Middle East Police Service with Deposit Received and Preliminary Design Work Underway for Lamperd: Stock Symbol: LLLI

Popular on PennZone

  • Neurosurgeon Chengyuan Wu, MD, MSBmE, Joins the Actuated Medical Advisory Board - 214
  • CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
  • Russellville Huntington Learning Center Expands Access to Literacy Support; Approved Provider Under Arkansas Department of Education
  • Stockwell Elastomerics expands micro molding capabilities
  • Price Improvement on Luxurious Lāna'i Townhome with Stunning Ocean Views
  • Together We Dance Foundation Announces Transformational Support from NAC Have a Heart Foundation
  • Lacy Hendricks Earns Prestigious MPM® Designation from NARPM®
  • Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
  • Harry Hayman Celebrates Years of WHYY Coverage, Partnership & Shared Commitment to Philadelphia
  • Robert DeMaio, Phinge Founder & CEO, Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes

Similar on PennZone

  • Acuvance Acquires ROI Healthcare Solutions, Building a Dedicated Healthcare ERP Practice
  • Appliance Outlet Caps Off a Record-Setting 2025 Nationwide, Gears Up for Even Greater Growth in 2026
  • CCHR White Paper Urges Government Crackdown on Troubled Teen and For-Profit Psychiatric Facilities
  • Still Searching for the Perfect Valentine's Gift? Lick Personal Oils Offers Romantic, Experience-Driven Alternatives to Traditional Presents
  • Automation, innovation in healthcare processes featured at international conference in Atlanta
  • High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
  • Ski Safety Awareness Month highlights why seeing clearly and wearing modern protection matters more than ever
  • Acmeware and Avo Partner to Bring Real-Time Data Integration to MEDITECH Customers
  • CCHR Says Mounting Evidence of Persistent Sexual Dysfunction From Antidepressants Demands FDA Action
  • New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us